NAMS Position Statement: The 2020 Genitourinary Syndrome of Menopause Position Statement of the North American Menopause Society

Menopause. 2020;27(9):976-992. 

In This Article


A nine-member Panel composed of expert clinicians and researchers in the field of genitourinary health reviewed the literature to evaluate new evidence on management strategies, including vaginal estrogens, vaginal dehydroepiandrosterone (DHEA), ospemifene, and other management options available or in development for symptomatic GSM. A literature search was conducted using the terms "genitourinary syndrome of menopause/GSM," "vulvovaginal atrophy/VVA," "atrophic vaginitis," "dyspareunia," "vaginal dryness," and "vaginal lubrication." If evidence was contradictory or inadequate to form a conclusion, a consensus-based opinion was established.

The Panel's completed draft of the updated Position Statement was submitted to the NAMS Board of Trustees for additional review, comments, and edits. The Board is composed of both clinicians and researchers from multiple specialties and disciplines. The Board approved the Position Statement with edits after final Panel review.